CEBPZ and acute myeloid leukemia: We postulated that reversal, early during therapy, of such a blast cell gene expression signature, may predict an emerging remission, and may reflect an epigenetic reprogramming of poor-risk/refractory AML toward enhanced sensitivity, associated with non-expression of HOXA, which mimics core-binding factor translocation-associated (CBF+ve) AML.[29]